Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Epizyme nets $160.4mm through concurrent offerings of common and preferred shares

Executive Summary

Epigenetics firm Epizyme Inc. netted $160.4mm through concurrent public offerings. The company sold 11.5mm common shares (including the overallotment) at $11.50 for net proceeds of $123mm, and also sold 350,000 Series A preferred shares (including the overallotment) at $115 for net proceeds of $37.4mm. Funds will support ongoing development, regulatory activities, and future commercialization of tazemetostat for epithelioid sarcoma and follicular lymphoma; R&D of other projects, including EZM8266 for sickle cell disease; and working capital.
Deal Industry
  • Biotechnology
    • Pharmacogenetics-Pharmacogenomics
  • In Vitro Diagnostics
    • Molecular Diagnostics & Genetic Testing
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • FOPO

Related Companies